
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k051122
B. Purpose for Submission:
New device
C. Measurand:
CMV specific MHC tetramer
D. Type of Test:
Flow cytometric assay
E. Applicant:
Beckman Coulter, Inc.
F. Proprietary and Established Names:
iTAg MHC Tetramer-CMV
G. Regulatory Information:
1. Regulation section:
21 CFR § 864.5220, Automated differential cell counter
2. Classification:
Class II
3. Product code:
GKZ, Counter, differential cell
4. Panel:
Hematology (81)
H. Intended Use:
1. Intended use(s):
The Beckman Coulter iTAg MHC Tetramer CMV assay is for the identification
and enumeration of cytomegalovirus (CMV)-specific CD8+ lymphocytes in
whole blood by flow cytometry, and for the assessment of CMV-specific immune
status and risk of CMV reactivation in immunosuppressed stem cell transplant
recipients. The assay is limited to individuals with the following HLA types:
A*0101, A*0201, B*0702, B*0801, B*3501.
2. Indication(s) for use:
Same as intended use.
3. Special conditions for use statement(s):
The device is for prescription use only.
4. Special instrument requirements:
Beckman Coulter Inc. (BCI) EPICS-XL using System II software, BCI FC500
using CXP software and Becton Dickinson (BD) FACSCalibur using CellQuest
software. BCI TQ Prep/ImmunoPrep for whole blood sample preparation (could
use other preparation instruments or use manual preparation).
I. Device Description:
The iTAg MHC Tetramer CMV Kit contains the following
1) iTAg MHC Tetramer Multi-Allele Start-UP – CMV (ready-to-use)

--- Page 2 ---
• iTAg MHC Negative Tetramer (peptide sequence with no known
specificity in humans)
• iTAg MHC A*0101 Class I, peptide sequence VTEHDTLLY
• iTAg MHC A*0201 Class I, peptide sequence NLVPMVATV
• iTAg MHC B*0702 Class I, peptide sequence TPRVTGGGAM
• iTAg MHC B*0801 Class I, peptide sequence ELRRKMMYM
• iTAg MHC B*3501 Class I, peptide sequence IPSINVHHY
(The HLA molecules have been modified to minimize non-antigen specific
CD8 mediated binding.)
The company also provides Start-Up for 3 alleles selected from five alleles
specified above. Individual iTAg MHC Tetramers can also be purchased.
2) iTAg MHC Tetramer T Cell Typing Kit (ready-to-use)
• anti-CD3-PC5 clone UCHT1 (recognizes the 20 kD epsilon chain of the
CD3 antigen)
• anti-CD4-PE clone SFCI12T4D11 (recognizes a 62 kD single-chain
transmembrane glycoptorein present CD4 antigen)
• anti-CD8-FITC clone SFCI21Thy2D3 (recognizes an epitope on the α
chain of the 76 kD dimeric CD8 antigen)
3) iTAg MHC Tetramer Accessory Product Group (ready-to-use)
• iTAg MHC Tetramer Lyse Reagent (use with fixative reagent)
• iTAg MHC Tetramer Fixative Reagent (use with lyse reagent)
4) Flow-Count™ Fluorospheres (ready-to-use)
Reagents required but not provided:
• Flow-Set™ Fluorospheres
• IMMUNO-TROL™ Control Cells
J. Substantial Equivalence Information:
1. Predicate device name(s):
tetraONE System for EPICS XL with CYTO-STAT tetraCHROME
2. Predicate 510(k) number(s):
k990172
3. Comparison with predicate:
Similarities
Item Device Predicate
Tetramer reagents tetraONE SYSTEM for
CD8-FITC + tetramer-PE + EPICS XL with CYTO-STAT
CD3-PC5 tetraCHROME
Intended Use Allows simultaneous Same
identification and enumeration
of lymphocyte subset in whole
blood by flow cytometry
Fluorochrome FITC, PE and PC5 Same except for addition of
ECD
Instrumentation Flow cytometer Same
Sample type Whole blood Same

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
			Tetramer reagents
CD8-FITC + tetramer-PE +
CD3-PC5			tetraONE SYSTEM for
EPICS XL with CYTO-STAT
tetraCHROME		
Intended Use			Allows simultaneous
identification and enumeration
of lymphocyte subset in whole
blood by flow cytometry			Same		
Fluorochrome			FITC, PE and PC5			Same except for addition of
ECD		
Instrumentation			Flow cytometer			Same		
Sample type			Whole blood			Same		

--- Page 3 ---
Differences
Item Device Predicate
Intended use CMV-specific CD8+ Total CD45+, total CD3+,
lymphocytes for assessment of total CD4+ and total CD8+
CMV-specific immune status lymphocytes for T
and risk of CMV reactivation in lymphocyte subset
immunosuppressed stem cell determination
transplant recipients. The assay
is limited to 5 HLA Class I
antigens – A*0101, A*0201,
B*0702, B*0801, B*3501
Cell type detected CMV-specific CD8 subset and Total T cells and T cell
T cell subsets subsets
Detection method Tetramers (complexes of MHC Monoclonal antibodies to
molecules associated with a specific epitopes on T cell
CMV specific peptide subsets
sequence)
Acquisition time Longer (rare events) Standard
Controls Negative tetramer (peptide not IMMUNO-TROL™ Control
found in human) and Cells
IMMUNO-TROL™ Control
Cells
Anticoagulant EDTA EDTA, ACD and sodium
heparin
K. Standard/Guidance Document Referenced (if applicable):
FDA Guidance Document for 510(k) Submission of Lymphocyte
Immunophenotyping Monoclonal Antibodies (9/91); CLSI Standard Method
Comparison and Bias Estimation Using Patient Samples; Approved Guideline (CLSI
Guideline EP9-A); CLSI Standard. Procedures for the Collection of Diagnostic Blood
Specimens by Venipuncture (CLSI Guideline H3-A5); CLSI Flow Cytometry:
Quality Assurance and Immunophenotyping of Lymphocytes (CLSI Guideline H42-
A) and CLSI Performance of Single Cell Immune Response Assays (CLSI Guideline
I/LA26-A).
L. Test Principle:
The test consists of two panels. The first panel, (T Cell Typing Kit) determines the
absolute count of T cell subsets per volume of blood. The second panel (MHC
Tetramer Multi-Allele Start-UP – CMV) determines the frequency of CMV-specific
cytotoxic T cells. Whole blood sample (EDTA) is incubated with the T Cell Typing
reagents (anti-CD3, anti-CD4 and anti-CD8) in tube 1 and in tube 2 with the CMV
specific MHC Tetramer Multi-Allele reagents (specific tetramers, anti-CD3 and anti-
CD8). After incubation and red blood cell lysis, the samples are centrifuged, and
supernatant aspirated. The remaining cell pellets are suspended and assayed on a
flow cytometer. In tube 1, the total CD3+ count is determined and a subset analysis
performed to count the CD3+CD4+ and CD3+CD8+ cells. In tube 2, the tetramer
positive cells are determined by subset analysis of the CD3+CD8+ cells. The
number of CMV-specific cytotoxic T cells per volume of blood is then determined by
combining the results of the two panels.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:

[Table 1 on page 3]
Differences								
	Item			Device			Predicate	
Intended use			CMV-specific CD8+
lymphocytes for assessment of
CMV-specific immune status
and risk of CMV reactivation in
immunosuppressed stem cell
transplant recipients. The assay
is limited to 5 HLA Class I
antigens – A*0101, A*0201,
B*0702, B*0801, B*3501			Total CD45+, total CD3+,
total CD4+ and total CD8+
lymphocytes for T
lymphocyte subset
determination		
Cell type detected			CMV-specific CD8 subset and
T cell subsets			Total T cells and T cell
subsets		
Detection method			Tetramers (complexes of MHC
molecules associated with a
CMV specific peptide
sequence)			Monoclonal antibodies to
specific epitopes on T cell
subsets		
Acquisition time			Longer (rare events)			Standard		
Controls			Negative tetramer (peptide not
found in human) and
IMMUNO-TROL™ Control
Cells			IMMUNO-TROL™ Control
Cells		
Anticoagulant			EDTA			EDTA, ACD and sodium
heparin		

--- Page 4 ---
Testing was performed using the BCI EPICS-XL flow cytometer. Since HLA-
A*0201 is the most common allele found in North American population,
analytical performance of the assay was determined using this allele and validated
on A*0101 and B*0702. In some studies, B*0801 and B*3501 were also tested.
The following table summarizes the HLA alleles used in the performance studies:
Analytical Study HLA-Specificities
HLA- HLA- HLA- HLA- HLA-
A*0201 A*0101 B*0702 B*0801 B*3501
Specificity (blood cell populations) (cid:57)
Specificity (non-CMV infectious (cid:57) (cid:57) (cid:57) (cid:57) (cid:57)
disease samples EBV+/CMV-)
Specificity (CMV+ samples with (cid:57) (cid:57) (cid:57) (cid:57) (cid:57)
allele/tetramer mismatched)
Linear range (cid:57) (cid:57) (cid:57)
Accuracy (cid:57) (cid:57) (cid:57) (cid:57) (cid:57)
Recovery (cid:57) (cid:57) (cid:57)
Sensitivity (cid:57) (cid:57) (cid:57)
Intra-lab reproducibility (cid:57) (cid:57) (cid:57) (cid:57) (cid:57)
Inter-lab reproducibility (cid:57) (cid:57) (cid:57)
Specimen collection and handling (cid:57) (cid:57) (cid:57)
Expected reference range (cid:57) (cid:57) (cid:57) (cid:57) (cid:57)
Flow cytometer instrument comparison (cid:57) (cid:57) (cid:57) (cid:57)
a. Precision/Reproducibility:
Intra-lab reproducibility was performed by three operators for the A*0101,
A*0201 and B*0702 CMV tetramers using 3 BCI EPICS-XL flow
cytometers. Separate determinations were made for panel 1 and panel 2.
Whole blood samples from 3 CMV-seropositive donors per allele were tested
at low < 0.7%), mid (0.7 to 2.0%) and high (> 2.0%) positive tetramer level.
Samples were tested in replicates of ten. Reproducibility was further
confirmed for B*0801 and B*3501 CMV tetramers by a single operator using
one donor per allele at a single CMV tetramer+ percent (a mid level for
B*0801 and low level for B*3501) and samples were also tested in replicates
of ten.
Operator 1 Operator 2 Operator 3
Tetramer+ Tetramer+ Tetramer+
Allele Level cells/μL SD %CV cells/μL SD %CV cells/μL SD %CV
Low 2.81 0.17 6.0 2.41 0.10 4.3 2.16 0.10 4.5
A*0101 Mid 4.60 0.22 4.8 4.52 0.27 6.0 4.81 0.15 3.2
High 30.65 0.39 1.3 29.26 0.96 3.3 28.49 0.72 2.5
Low 2.06 0.14 6.8 1.79 0.10 5.6 1.83 0.12 6.4
A*0201 Mid 8.62 0.41 4.7 8.02 0.33 4.1 7.54 0.22 2.9
High 14.30 0.44 3.1 12.26 0.35 2.8 13.15 0.42 3.2
Low 2.38 0.16 6.6 2.69 0.18 6.7 2.44 0.19 8.0
B*0702 Mid 4.76 0.24 5.0 4.10 0.21 5.0 4.52 0.36 7.9
High 24.54 0.78 3.2 22.67 0.64 2.8 22.10 0.42 1.9
B*0801 Mid 3.81 0.61 16.1
B*3501 Low 1.23 0.18 14.4

[Table 1 on page 4]
Analytical Study	HLA-Specificities				
	HLA-
A*0201	HLA-
A*0101	HLA-
B*0702	HLA-
B*0801	HLA-
B*3501
Specificity (blood cell populations)	(cid:57)				
Specificity (non-CMV infectious
disease samples EBV+/CMV-)	(cid:57)	(cid:57)	(cid:57)	(cid:57)	(cid:57)
Specificity (CMV+ samples with
allele/tetramer mismatched)	(cid:57)	(cid:57)	(cid:57)	(cid:57)	(cid:57)
Linear range	(cid:57)	(cid:57)	(cid:57)		
Accuracy	(cid:57)	(cid:57)	(cid:57)	(cid:57)	(cid:57)
Recovery	(cid:57)	(cid:57)	(cid:57)		
Sensitivity	(cid:57)	(cid:57)	(cid:57)		
Intra-lab reproducibility	(cid:57)	(cid:57)	(cid:57)	(cid:57)	(cid:57)
Inter-lab reproducibility	(cid:57)	(cid:57)	(cid:57)		
Specimen collection and handling	(cid:57)	(cid:57)	(cid:57)		
Expected reference range	(cid:57)	(cid:57)	(cid:57)	(cid:57)	(cid:57)
Flow cytometer instrument comparison	(cid:57)	(cid:57)	(cid:57)		(cid:57)

[Table 2 on page 4]
Allele	Level	Operator 1			Operator 2			Operator 3		
		Tetramer+
cells/μL	SD	%CV	Tetramer+
cells/μL	SD	%CV	Tetramer+
cells/μL	SD	%CV
A*0101	Low	2.81	0.17	6.0	2.41	0.10	4.3	2.16	0.10	4.5
	Mid	4.60	0.22	4.8	4.52	0.27	6.0	4.81	0.15	3.2
	High	30.65	0.39	1.3	29.26	0.96	3.3	28.49	0.72	2.5
A*0201	Low	2.06	0.14	6.8	1.79	0.10	5.6	1.83	0.12	6.4
	Mid	8.62	0.41	4.7	8.02	0.33	4.1	7.54	0.22	2.9
	High	14.30	0.44	3.1	12.26	0.35	2.8	13.15	0.42	3.2
B*0702	Low	2.38	0.16	6.6	2.69	0.18	6.7	2.44	0.19	8.0
	Mid	4.76	0.24	5.0	4.10	0.21	5.0	4.52	0.36	7.9
	High	24.54	0.78	3.2	22.67	0.64	2.8	22.10	0.42	1.9
B*0801	Mid	3.81	0.61	16.1						
B*3501	Low	1.23	0.18	14.4						

--- Page 5 ---
Operator 1 Operator 2 Operator 3
% % %
Allele Level Tetramer+ SD %CV Tetramer+ SD %CV Tetramer+ SD %CV
Low 0.92 0.05 5.9 0.87 0.04 4.3 0.84 0.04 4.4
A*0101 Mid 1.12 0.05 4.8 1.13 0.07 6.0 1.10 0.04 3.2
High 5.15 0.07 1.3 5.36 0.18 3.3 5.11 0.13 2.5
Low 0.53 0.04 7.1 0.47 0.03 5.6 0.50 0.03 6.3
A*0201 Mid 2.13 0.10 4.7 2.03 0.08 4.0 1.96 0.06 2.9
High 3.47 0.11 3.1 3.50 0.10 2.8 3.44 0.11 3.2
Low 0.77 0.05 6.6 0.88 0.06 6.7 0.71 0.05 7.7
B*0702 Mid 1.14 0.06 5.1 1.14 0.06 5.0 1.20 0.09 7.8
High 5.99 0.19 3.2 5.79 0.16 2.8 5.70 0.11 1.9
B*0801 Mid 0.78 0.13 16.3
B*3501 Low 0.25 0.04 14.5
Inter-lab reproducibility was performed at three sites for the A*0101, A*0201
and B*0702 CMV tetramers using 3 BCI EPICS-XL flow cytometers by 3
operators. The 3 sites were within the BCI facility. Separate determinations
were made for panel 1 and panel 2. Whole blood samples from 3 CMV-
seropositive donors per allele were tested at low < 0.7%), mid (0.7 to 2.0%)
and high (> 2.0%) positive tetramer level. Samples were tested in replicates
of ten.
Tetramer+ % CD3+CD8+
Allele Level cells/μL SD %CV Tetramer+ SD %CV cells/μL SD %CV
Low 2.46 0.33 13.3 0.88 0.04 4.6 281 24.3 8.7
A*0101 Mid 4.64 0.15 3.2 1.12 0.02 1.4 416 19 4.6
High 29.47 1.09 3.7 5.21 0.13 2.6 566 25.5 4.5
Low 1.89 0.15 7.7 0.50 0.03 6.0 378 9 2.4
A*0201 Mid 8.06 0.54 6.7 2.04 0.09 4.2 395 10.5 2.7
High 13.27 0.98 7.4 3.47 0.03 0.9 382 29.5 7.7
Low 2.50 0.16 6.6 0.79 0.09 11.0 321 21.7 6.8
B*0702 Mid 4.46 0.33 7.5 1.16 0.03 3.0 384 28.4 7.4
High 23.10 1.28 5.5 5.83 0.15 2.5 396 11.9 3.0
Additional inter-lab reproducibility was performed at BCI and two external
sites (one US and one Canadian) with whole blood samples from 11 CMV-
seropositive donors. External Site A had one operator using BD FACSCalibur
flow cytometer. Both External Site B and the BCI site had two operators
using BCI EPICS-XL and FC500 flow cytometers. Whole blood was
collected and tested with 24-72 hours of venipuncture. Samples included both
low and mid concentrations of CMV tetramer+ cells. Samples were assayed
in duplicate but only the first replicate was used for the analysis to reflect the
normal clinical use of the device. Twenty-one results were generated (4
A*0101, 11 A*0201 and 6 B*0702).
Tetramer+ % CD3+CD8+
Sample cells/μL SD %CV Tetramer+ SD %CV cells/μL SD %CV
1 0.68 0.14 19.9 0.23 0.05 20.8 299 34.0 11.4
2 0.79 0.05 6.8 0.42 0.05 12.5 189 11.4 6.1
3 0.79 0.07 8.6 0.48 0.05 11.1 164 10.9 6.7
4 0.87 0.22 25.8 0.17 0.06 12.5 496 63.4 12.8
5 1.00 0.22 21.7 0.48 0.06 12.9 209 21.4 10.2
6 1.73 0.29 17.1 0.46 0.07 15.6 379 68.4 18.1

[Table 1 on page 5]
Allele	Level	Operator 1			Operator 2			Operator 3		
		%
Tetramer+	SD	%CV	%
Tetramer+	SD	%CV	%
Tetramer+	SD	%CV
A*0101	Low	0.92	0.05	5.9	0.87	0.04	4.3	0.84	0.04	4.4
	Mid	1.12	0.05	4.8	1.13	0.07	6.0	1.10	0.04	3.2
	High	5.15	0.07	1.3	5.36	0.18	3.3	5.11	0.13	2.5
A*0201	Low	0.53	0.04	7.1	0.47	0.03	5.6	0.50	0.03	6.3
	Mid	2.13	0.10	4.7	2.03	0.08	4.0	1.96	0.06	2.9
	High	3.47	0.11	3.1	3.50	0.10	2.8	3.44	0.11	3.2
B*0702	Low	0.77	0.05	6.6	0.88	0.06	6.7	0.71	0.05	7.7
	Mid	1.14	0.06	5.1	1.14	0.06	5.0	1.20	0.09	7.8
	High	5.99	0.19	3.2	5.79	0.16	2.8	5.70	0.11	1.9
B*0801	Mid	0.78	0.13	16.3						
B*3501	Low	0.25	0.04	14.5						

[Table 2 on page 5]
Allele	Level	Tetramer+
cells/μL	SD	%CV	%
Tetramer+	SD	%CV	CD3+CD8+
cells/μL	SD	%CV
A*0101	Low	2.46	0.33	13.3	0.88	0.04	4.6	281	24.3	8.7
	Mid	4.64	0.15	3.2	1.12	0.02	1.4	416	19	4.6
	High	29.47	1.09	3.7	5.21	0.13	2.6	566	25.5	4.5
A*0201	Low	1.89	0.15	7.7	0.50	0.03	6.0	378	9	2.4
	Mid	8.06	0.54	6.7	2.04	0.09	4.2	395	10.5	2.7
	High	13.27	0.98	7.4	3.47	0.03	0.9	382	29.5	7.7
B*0702	Low	2.50	0.16	6.6	0.79	0.09	11.0	321	21.7	6.8
	Mid	4.46	0.33	7.5	1.16	0.03	3.0	384	28.4	7.4
	High	23.10	1.28	5.5	5.83	0.15	2.5	396	11.9	3.0

[Table 3 on page 5]
Sample	Tetramer+
cells/μL	SD	%CV	%
Tetramer+	SD	%CV	CD3+CD8+
cells/μL	SD	%CV
1	0.68	0.14	19.9	0.23	0.05	20.8	299	34.0	11.4
2	0.79	0.05	6.8	0.42	0.05	12.5	189	11.4	6.1
3	0.79	0.07	8.6	0.48	0.05	11.1	164	10.9	6.7
4	0.87	0.22	25.8	0.17	0.06	12.5	496	63.4	12.8
5	1.00	0.22	21.7	0.48	0.06	12.9	209	21.4	10.2
6	1.73	0.29	17.1	0.46	0.07	15.6	379	68.4	18.1

--- Page 6 ---
Tetramer+ % CD3+CD8+
Sample cells/μL SD %CV Tetramer+ SD %CV cells/μL SD %CV
7 1.52 0.21 13.7 0.66 0.07 11.2 231 28.6 12.3
8 1.84 0.18 10.0 0.76 0.04 5.0 241 15.5 6.4
9 2.33 0.26 11.3 0.82 0.05 6.4 284 37.1 13.1
10 2.76 0.70 25.2 0.80 0.16 20.6 344 26.4
11 3.01 0.33 11.1 0.90 0.12 12.9 337 11.6 3.4
12 2.97 0.66 22.3 0.93 0.12 13.3 315 31.7 10.1
13 4.39 1.30 29.6 1.26 0.07 5.9 351 118.1 33.7
14 3.97 1.03 26.1 1.46 0.30 20.9 269 18.5 6.9
15 4.72 0.75 15.8 1.37 0.26 18.9 347 25.2 7.3
16 5.48 0.88 16.1 1.63 0.13 7.8 336 35.8 10.6
17 6.06 0.73 12.1 1.41 0.07 4.7 429 43.2 10.1
18 6.24 0.50 8.1 1.23 0.03 2.6 507 41.5 8.2
19 6.46 0.55 8.5 1.34 0.16 12.2 485 27.9 5.8
20 8.08 1.51 18.7 1.55 0.35 22.8 528 27.4 5.2
21 8.95 0.63 7.1 3.14 0.14 4.4 285 17.4 6.1
The %CV for intra-lab reproducibility ranged between 1.3% and 16.3%. The
%CV for inter-lab ranged from 0.9% to 13.3% when performed at BCI
facilities and from 2.6% to 29.6% when performed at BCI and two external
sites.
b. Linearity/assay reportable range:
Linearity - The assay linear range was determined using whole blood samples
from three CMV-seronegative donors spiked with CMV peptide-stimulated T
cells. The spiked whole blood samples were serially diluted to 14
concentrations across the assay range. Samples were tested in duplicate.
Results of linearity study are shown in table.
A*0101-CMV+ A*0201-CMV+ B*0702-CMV+
Tetramer+ Tetramer+ Tetramer+ Tetramer+ Tetramer+ Tetramer+
cells/µL cells/µL cells/µL cells/µL cells/µL cells/µL
Dilutions N expected actual expected actual expected actual
Neat 2 310.1 314.4 115.99 119.06 234.00 236.28
1:2.1 2 148.0 169.4 57.99 60.62 117.00 107.23
1;4.5 2 69.6 64.4 29.00 30.05 58.50 46.37
1:9.6 2 32.8 33.7 14.50 16.00 29.25 24.43
1:20.4 2 15.4 14.7 7.25 8.34 14.63 11.22
1:43.3 2 7.3 6.7 3.62 3.93 7.31 5.44
1:92 2 3.4 3.9 1.81 2.33 3.66 2.58
1:184 2 1.7 1.6 0.91 1.33 1.83 1.51
1:368 2 0.9 0.9 0.45 0.81 0.91 0.57
1:736 2 0.4 0.2 0.23 0.35 0.46 0.28
1:1473 2 0.2 0.2 0.11 0.21 0.23 0.13
1:2946 2 0.1 0.1 0.06 0.14 0.11 0.05
1:5892 2 0.1 0.0 0.03 0.03 0.06 0.03
1:11785 2 0.0 0.0 0.01 0.03 0.03 0.03
Deming regression analyses are summarized in following table:
%Tetramers+ Tetramer+ cells/μL
Regression parameter N=2 N=2 95% CI
A*0101 R value 0.9891 0.998 0.993 to 0.999
Slope 1.0640 1.04 0.997 to 1.08
Intercept 0.6423 0.18 -1.59 to 1.87

[Table 1 on page 6]
Sample	Tetramer+
cells/μL	SD	%CV	%
Tetramer+	SD	%CV	CD3+CD8+
cells/μL	SD	%CV
7	1.52	0.21	13.7	0.66	0.07	11.2	231	28.6	12.3
8	1.84	0.18	10.0	0.76	0.04	5.0	241	15.5	6.4
9	2.33	0.26	11.3	0.82	0.05	6.4	284	37.1	13.1
10	2.76	0.70	25.2	0.80	0.16	20.6	344	26.4	
11	3.01	0.33	11.1	0.90	0.12	12.9	337	11.6	3.4
12	2.97	0.66	22.3	0.93	0.12	13.3	315	31.7	10.1
13	4.39	1.30	29.6	1.26	0.07	5.9	351	118.1	33.7
14	3.97	1.03	26.1	1.46	0.30	20.9	269	18.5	6.9
15	4.72	0.75	15.8	1.37	0.26	18.9	347	25.2	7.3
16	5.48	0.88	16.1	1.63	0.13	7.8	336	35.8	10.6
17	6.06	0.73	12.1	1.41	0.07	4.7	429	43.2	10.1
18	6.24	0.50	8.1	1.23	0.03	2.6	507	41.5	8.2
19	6.46	0.55	8.5	1.34	0.16	12.2	485	27.9	5.8
20	8.08	1.51	18.7	1.55	0.35	22.8	528	27.4	5.2
21	8.95	0.63	7.1	3.14	0.14	4.4	285	17.4	6.1

[Table 2 on page 6]
Dilutions	N	A*0101-CMV+		A*0201-CMV+		B*0702-CMV+	
		Tetramer+
cells/µL
expected	Tetramer+
cells/µL
actual	Tetramer+
cells/µL
expected	Tetramer+
cells/µL
actual	Tetramer+
cells/µL
expected	Tetramer+
cells/µL
actual
Neat	2	310.1	314.4	115.99	119.06	234.00	236.28
1:2.1	2	148.0	169.4	57.99	60.62	117.00	107.23
1;4.5	2	69.6	64.4	29.00	30.05	58.50	46.37
1:9.6	2	32.8	33.7	14.50	16.00	29.25	24.43
1:20.4	2	15.4	14.7	7.25	8.34	14.63	11.22
1:43.3	2	7.3	6.7	3.62	3.93	7.31	5.44
1:92	2	3.4	3.9	1.81	2.33	3.66	2.58
1:184	2	1.7	1.6	0.91	1.33	1.83	1.51
1:368	2	0.9	0.9	0.45	0.81	0.91	0.57
1:736	2	0.4	0.2	0.23	0.35	0.46	0.28
1:1473	2	0.2	0.2	0.11	0.21	0.23	0.13
1:2946	2	0.1	0.1	0.06	0.14	0.11	0.05
1:5892	2	0.1	0.0	0.03	0.03	0.06	0.03
1:11785	2	0.0	0.0	0.01	0.03	0.03	0.03

[Table 3 on page 6]
	Regression parameter	%Tetramers+	Tetramer+ cells/μL	
		N=2	N=2	95% CI
A*0101	R value	0.9891	0.998	0.993 to 0.999
	Slope	1.0640	1.04	0.997 to 1.08
	Intercept	0.6423	0.18	-1.59 to 1.87

--- Page 7 ---
%Tetramers+ Tetramer+ cells/μL
Regression parameter N=2 N=2 95% CI
A*0201 R value 0.9891 0.999 0.999 to 1.00
Slope 1.0498 1.03 1.02 to 1.03
Intercept 1.0183 0.35 0.23 to 0.47
B*0702 R value 0.9962 0.998 0.993 to 0.999
Slope 1.0322 0.99 0.96 to 1.03
Intercept 0.4502 -2.06 -3.37 to -0.81
Results showed acceptable correlation between the expected and actual values
for absolute counts of CMV tetramer positive cells. Depending on the sample
tested, the upper limit of the linear range for the tetramer-positive cells varied
by allele and ranges from 119 cells/µL (A*0201) to >300 cells/µL (A*0101).
Recovery – This study was performed according to FDA 510(k)
Immunophenotyping Guidance. Whole blood sample from one CMV-
seronegative donor per allele (A*0101, A*0201 and B*0702) was spiked with
blood from a CMV-seropositive HLA matched donor to 3 tetramer levels
(low, mid and high). Separate determinations were made for panel 1 and
panel 2 and samples were tested in replicates of five. Results for tetramer+
absolute counts and percents are shown below.
Expected Observed
Spiked Tetramer+ Tetramer + % Mean
Allele Level N cells/μL cells/μL SD %CV Recovery Recovery
Low 5 3.14 3.37 0.2 5.81 107
A*0101 Mid 5 9.23 9.26 0.17 1.8 100 102
High 5 15.91 15.92 0.37 2.29 100
Low 5 0.52 0.43 0.08 17.92 83
A*0201 Mid 5 1.54 1.29 0.06 4.4 84 84
High 5 2.46 2.13 0.07 3.31 86
Low 5 2.55 2.49 0.24 9.32 98
B*0702 Mid 5 7.83 7.70 0.19 2.38 98 97
High 5 12.14 11.68 0.3 2.5 96
Spiked Expected Observed % Mean
Allele Level N %Tetramer+ %Tetramer + SD %CV Recovery Recovery
Low 5 1.29 1.40 0.08 5.71 109
A*0101 Mid 5 2.92 2.96 0.06 1.87 101 104
High 5 3.92 3.95 0.09 2.24 101
Low 5 0.12 0.10 0.02 18.25 83
A*0201 Mid 5 0.39 0.34 0.02 4.86 88 87
High 5 0.73 0.66 0.02 3.63 90
Low 5 0.63 0.62 0.06 8.91 99
B*0702 Mid 5 1.86 1.86 0.04 2.4 100 99
High 5 3.07 3.01 0.08 2.54 98
The overall percent recovery across the three tetramers was 96%.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
No reference material and method available.
d. Detection limit:
Functional assay sensitivity is defined as the lowest concentration where the
CV is ≤ 20%. Results generated in the linear range study were used for the

[Table 1 on page 7]
	Regression parameter	%Tetramers+	Tetramer+ cells/μL	
		N=2	N=2	95% CI
A*0201	R value	0.9891	0.999	0.999 to 1.00
	Slope	1.0498	1.03	1.02 to 1.03
	Intercept	1.0183	0.35	0.23 to 0.47
B*0702	R value	0.9962	0.998	0.993 to 0.999
	Slope	1.0322	0.99	0.96 to 1.03
	Intercept	0.4502	-2.06	-3.37 to -0.81

[Table 2 on page 7]
Allele	Spiked
Level	N	Expected
Tetramer+
cells/μL	Observed
Tetramer +
cells/μL	SD	%CV	%
Recovery	Mean
Recovery
A*0101	Low	5	3.14	3.37	0.2	5.81	107	102
	Mid	5	9.23	9.26	0.17	1.8	100	
	High	5	15.91	15.92	0.37	2.29	100	
A*0201	Low	5	0.52	0.43	0.08	17.92	83	84
	Mid	5	1.54	1.29	0.06	4.4	84	
	High	5	2.46	2.13	0.07	3.31	86	
B*0702	Low	5	2.55	2.49	0.24	9.32	98	97
	Mid	5	7.83	7.70	0.19	2.38	98	
	High	5	12.14	11.68	0.3	2.5	96	

[Table 3 on page 7]
Allele	Spiked
Level	N	Expected
%Tetramer+	Observed
%Tetramer +	SD	%CV	%
Recovery	Mean
Recovery
A*0101	Low	5	1.29	1.40	0.08	5.71	109	104
	Mid	5	2.92	2.96	0.06	1.87	101	
	High	5	3.92	3.95	0.09	2.24	101	
A*0201	Low	5	0.12	0.10	0.02	18.25	83	87
	Mid	5	0.39	0.34	0.02	4.86	88	
	High	5	0.73	0.66	0.02	3.63	90	
B*0702	Low	5	0.63	0.62	0.06	8.91	99	99
	Mid	5	1.86	1.86	0.04	2.4	100	
	High	5	3.07	3.01	0.08	2.54	98	

--- Page 8 ---
calculation. Serial dilutions for B*0702 were repeated because results were
inconsistent to previous determinations. Functional sensitivity was
determined to be 1.0 cell/µL for absolute counts and 0.2% for percent of
tetramer positive CD8+ cells (see table below).
% Tetramer+ Tetramer+ cells/μL
Allele N=2 N=2
A*0101 0.16 0.87
A*0201 0.19 0.35
B*0702 0.44 1.51
B*0702 (repeat) 0.16 0.64
Mean B*0702 0.30 1.08
Overall Mean 0.22 0.77
Overall SD 0.07 0.37
e. Analytical specificity:
Interference by other cell types - The potential interference of monocytes,
granulocytes, platelets and red blood cells was determined for the A*0201
tetramer according to the FDA 510(k) Immunophenotyping Guidance. Whole
blood samples from three CMV-seropositive apparently healthy donors with
low, moderate and high % tetramers were used and were spiked with each test
cell population. For each test cell population, three different concentrations of
spiked cell (1x, 2x or 3x the normal cell count) were tested. Monocytes,
granulocytes and platelets were tested in replicates of three and red blood cells
in replicates of five. There was no significant interference from the tested cell
populations at levels up to 900 cells/μL (equivalent to 3x normal level) for
monocytes (median percent recovery 105% ranged from 93% to 108%); 5000
cells/μL (2x level) for granulocytes (median percent recovery 100% ranged
92% to 108%), 3.2x105 cells/μL (2x level) for platelets (median percent
recovery 95% ranged from 88% to 96%) and 1.31x107 cells/μL (3x level) for
red blood cells (median recovery 104% ranged from 104% to 112%). Results
are summarized below:
Cell Type Spiked Low % tetramer Mid % tetramer High % tetramer
cell Mean SD %CV % Mean SD %CV % Mean SD %CV %
conc. Recovery Recovery Recovery
Monocytes 1x 0.13 0 0 100 1.57 0.02 1.3 100 1.78 0.06 3.6 100
2x 0.14 0.03 18.3 110 1.48 0.07 4.4 94 1.85 0.12 6.7 104
3x 0.14 0.03 21.4 108 1.46 0.04 2.8 93 1.86 0.01 0.7 105
Granulocytes 1x 0.13 0 0 100 1.57 0.02 1.3 100 1.78 0.06 3.6 100
2x 0.13 0.01 6.3 100 1.45 0.06 4.1 92 1.92 0.13 6.6 108
3x 0.12 0.02 13.8 95 1.20 0.03 2.8 76 1.75 0.11 6.4 98
Platelets 1x 0.13 0 0 100 1.57 0.02 1.3 100 1.78 0.06 3.6 100
2x 0.12 0 3.8 96 1.37 0.11 7.9 88 1.7 0.07 4.1 95
3x 0.12 0.02 13.8 95 1.32 0.05 4.1 84 1.62 0.03 1.8 91
Red cells 1x 0.18 0.01 8.13 100 0.64 0.05 7.83 100 1.86 0.05 2.46 100
2x 0.20 0.02 12.33 107 0.74 0.07 10.08 115 1.93 0.11 5.5 103
3x 0.21 0.01 5.83 112 0.67 0.03 5.17 104 2.01 0.03 1.53 108
Cross-reactivity with EBV – Whole blood samples from 14 EBV-seropositive,
CMV-seronegative, apparently healthy honors with HLA specificities of were

[Table 1 on page 8]
Allele	% Tetramer+	Tetramer+ cells/μL
	N=2	N=2
A*0101	0.16	0.87
A*0201	0.19	0.35
B*0702	0.44	1.51
B*0702 (repeat)	0.16	0.64
Mean B*0702	0.30	1.08
Overall Mean	0.22	0.77
Overall SD	0.07	0.37

[Table 2 on page 8]
Cell Type	Spiked
cell
conc.	Low % tetramer				Mid % tetramer				High % tetramer			
		Mean	SD	%CV	%
Recovery	Mean	SD	%CV	%
Recovery	Mean	SD	%CV	%
Recovery
Monocytes	1x	0.13	0	0	100	1.57	0.02	1.3	100	1.78	0.06	3.6	100
	2x	0.14	0.03	18.3	110	1.48	0.07	4.4	94	1.85	0.12	6.7	104
	3x	0.14	0.03	21.4	108	1.46	0.04	2.8	93	1.86	0.01	0.7	105
Granulocytes	1x	0.13	0	0	100	1.57	0.02	1.3	100	1.78	0.06	3.6	100
	2x	0.13	0.01	6.3	100	1.45	0.06	4.1	92	1.92	0.13	6.6	108
	3x	0.12	0.02	13.8	95	1.20	0.03	2.8	76	1.75	0.11	6.4	98
Platelets	1x	0.13	0	0	100	1.57	0.02	1.3	100	1.78	0.06	3.6	100
	2x	0.12	0	3.8	96	1.37	0.11	7.9	88	1.7	0.07	4.1	95
	3x	0.12	0.02	13.8	95	1.32	0.05	4.1	84	1.62	0.03	1.8	91
Red cells	1x	0.18	0.01	8.13	100	0.64	0.05	7.83	100	1.86	0.05	2.46	100
	2x	0.20	0.02	12.33	107	0.74	0.07	10.08	115	1.93	0.11	5.5	103
	3x	0.21	0.01	5.83	112	0.67	0.03	5.17	104	2.01	0.03	1.53	108

--- Page 9 ---
HLA A*0101, A*0201, B*0702, B*0801 and B*3501tested. Samples were
tested in duplicate. There were a total of 22 tetramer results and no cross-
reactivity was observed. All results were below the lower assay detection
limit for absolute count (≤1.0 cells/μL) and percent of positive cells (≤ 0.2%)
(see table below).
CMV Tetramer+
# Tetramer results = 22 Cells/μL Percent (%)
Median 0.03 0.005
Mean ± SD 0.09 ± 0.16 0.018 ± 0.031
Range 0 to 0.64 0 to 0.130
Upper 95th Percentile 0.48 0.074
Mismatched donor HLA allele and tetramer combinations – Whole blood
samples from five CMV-seropositive apparently healthy donors were tested
using mismatched tetramers for each donor. HLA alleles of the donors
included A*0101, A*0201, B*0702, B*0801 and B*3501. Samples were
tested in duplicate. Of the 19 combinations, no cross-reactivity was observed
(see results below). All results were below the lower assay detection limit for
absolute count (≤1.0 cells/μL) and percent of positive cells (≤ 0.2%).
CMV Tetramer+
# Tetramer results = 19 Cells/μL Percent (%)
Median 0.03 0.010
Mean ± SD 0.09 ± 0.13 0.016 ± 0.021
Range 0.01 to 0.56 0 to 0.085
Upper 95th Percentile 0.32 0.055
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Comparison of T cell subsets – T cell subset results generated using T Cell
Typing Kit with the new device were compared to results of the predicate
assay Beckman Coulter tetraONE/tetraCHROME assay according to CLSI
Guideline EP9-A. Whole blood samples from 76 healthy donors (equal
number of CMV-seropositive and seronegative) were tested. Samples were
tested in duplicate. Results were analyzed by Deming regression for absolute
counts of CD3+CD8+ and CD3+CD4+ and summarized below:
T subset Slope 95% CI Intercept 95% CI R
CD3+CD8+ 1.12 1.06 to1.18 -15.19 -40.78 to 8.82 0.97
CD3+CD4+ 1.08 1.03 to 1.14 0.76 -42.23 to 41.47 0.98
In addition to comparing to the predicate, % recovery for CD3+CD8+ subset
detected by Panel 1 was compared to Panel 2 of the new device.

[Table 1 on page 9]
# Tetramer results = 22	CMV Tetramer+	
	Cells/μL	Percent (%)
Median	0.03	0.005
Mean ± SD	0.09 ± 0.16	0.018 ± 0.031
Range	0 to 0.64	0 to 0.130
Upper 95th Percentile	0.48	0.074

[Table 2 on page 9]
# Tetramer results = 19	CMV Tetramer+	
	Cells/μL	Percent (%)
Median	0.03	0.010
Mean ± SD	0.09 ± 0.13	0.016 ± 0.021
Range	0.01 to 0.56	0 to 0.085
Upper 95th Percentile	0.32	0.055

[Table 3 on page 9]
T subset	Slope	95% CI	Intercept	95% CI	R
CD3+CD8+	1.12	1.06 to1.18	-15.19	-40.78 to 8.82	0.97
CD3+CD4+	1.08	1.03 to 1.14	0.76	-42.23 to 41.47	0.98

--- Page 10 ---
Comparison Slope 95% CI Intercept 95% CI R
New vs. predicate 1.02 0.99 to 1.05 -0.13 -1.24 to 0.93 0.99
Panel 1 vs. Panel 2 1.00 0.97 to 1.03 -0.21 -1.18 to 0.73 0.99
Instrument comparison:
BD FACSCalibur flow cytometer vs. BCI EPICS-XL flow cytometer – Two
separate instruments from each manufacturer were tested at a single site with
the A*0101, A*0201, B*0702 and B*3501 CMV tetramers. The same gating
scheme and protocol were used. Whole blood samples from 16 CMV-
seropositive donors were tested in duplicate. These subjects had CMV
tetramer+ values within the expected reference range. Deming regression
analysis for tetramer+ absolute counts gave an equation of y = 0.9697x –
0.3255. The 95% CI for slope and intercept were (0.9383 to 1.0021) and (-
0.6315 to -0.0291) respectively. The correlation coefficient (r) was 0.9978.
Deming regression analysis for % tetramer-positive CD8 cells gave an
equation of y = 0.9800x – 0.0152. The 95% CI for slope and intercept were
(0.9514 to 1.0094) and (-0.0744 to 0.0424) respectively. The correlation
coefficient (r) was 0.9982.
Deming regression analysis for absolute CD3+CD8+ counts gave an equation
of y = 0.9520x + 1.3572. The 95% CI for slope and intercept were (0.9075 to
0.9986) and (-16.4046 to 18.3298) respectively. The correlation coefficient
(r) was 0.9954. Deming regression analysis for % CD3+CD8+ cells gave an
equation of y = 1.0061x – 0.5339. The 95% CI for slope and intercept were
(0.9602 to 1.0541) and (-2.1255 to 0.9848) respectively. The correlation
coefficient (r) was 0.9956.
The BCI EPICS-XL flow cytometer was also compared to the BCI FC500
flow cytometer with HLA A*0101, A*0201 and B*0702 CMV tetramers.
One instrument was used for each flow cytometer and all testing were
performed at a single site. Whole blood samples from seven apparently
healthy CMV-seronegative and 14 CMV-seropositive donors were tested in
duplicate with a total of 53 tetramer results. Deming regression analyses for
tetramer absolute counts yielded y = 0.9812x + 0.1527 (r = 0.9921) with 95%
CI for slope and intercept of (0.9472 to 1.0165) and (-0.0009 to 0.3011)
respectively. Deming regression analysis for % tetramer-positive CD8 cells
yielded y = 1.0426x – 0.0448 (r = 0.995) with 95% CI for slope and intercept
of (1.0138 to 1.0723) and (-0.0773 to -0.0133) respectively.
The imprecision for the CMV tetramer+ absolute counts was comparable
between instruments with average %CV < 10% for all samples tested.
b. Matrix comparison:
Only EDTA whole blood was used in this device.
3. Clinical studies:
a. Clinical Sensitivity and Specificity:

[Table 1 on page 10]
Comparison	Slope	95% CI	Intercept	95% CI	R
New vs. predicate	1.02	0.99 to 1.05	-0.13	-1.24 to 0.93	0.99
Panel 1 vs. Panel 2	1.00	0.97 to 1.03	-0.21	-1.18 to 0.73	0.99

--- Page 11 ---
Not applicable.
b. Other clinical supportive data (when a is not applicable):
Risk assessment
A retrospective feasibility study was performed on 18 CMV-seropositive stem
cell transplant (SCT) recipients who were monitored for recovery of CMV-
specific CTLs during the first 12 months after SCT. HLA-A2 tetramers were
used to quantify CMV-specific CD8+ T cells by flow cytometry. The kinetics
of regeneration of these CD8+ T cells was determined by enumeration of the
tetramer+ CD8+ cells at 2, 3, 6, 9 and 12 months post SCT and CMV pp65
antigenemia was monitored weekly from day 0 to day 150 and at longer
intervals thereafter. Serious post transplant outcomes were defined as
multiple (≥ 2) episodes of high viral reactivation requiring antiviral therapy, ≥
4 weeks on ganciclovir or foscarnet, CMVD, or transplant-related mortality.
Relative risk was analyzed by maximum tetramer levels in the first 100 days
post transplant. Results of this study showed patients with < 2 cells/µL were
4.4 and 1.8 times more likely to have recurrent CMV reactivation and CMVD
respectively.
Based on these findings, a prospective feasibility study was conducted. The
prospective study consisted of 15 allogeneic SCT transplant patients who were
followed up to 664 days post transplant for recurrence of CMV and
determination of number of tetramer-binding CMV-specific CD8+ T cells.
Tetramers used included HLA A80101, A*0201, A*2401, B*0702, B*0801
and B*3501. Results showed nine patients had recovered tetramer-binding
CMV-specific CD8+ T cells to levels ≥2 cells/μL (Group 1) in the first 2 to 3
months post transplant and eight of the nine patients (89%) did not develop
recurrent CMV infections. Of the remaining six patients had <2 cells/μL of
CMV-specific CD8+ T cells (Group 2), three (50%) had recurrent CMV
infections (see table below).
Recurrent Viremia
Yes No Total
CMV-Specific ≥ 2 cells/μL 1 8 9
CD8+ T cells < 2 cells/μL 3 3 6
Total 3 11 15
Study results, therefore, confirmed the initial results, i.e. patients with < 2
CMV-specific CD8+ T cells/µL were 4.5 times more likely to have recurrent
CMV complications.
Since the feasibility studies used a prototype tetramer assay, a comparison
study with 24 samples on the prototype and the final assay was performed.
Regression analysis gave y = 1.04x + 2.2 with r = 0.9899.
The prospective pivotal study was conducted at three clinical sites, two in the
US and one in Europe. Sample size calculations for the pivotal trial were

[Table 1 on page 11]
		Recurrent Viremia		
		Yes	No	Total
CMV-Specific
CD8+ T cells	≥ 2 cells/μL	1	8	9
	< 2 cells/μL	3	3	6
	Total	3	11	15

--- Page 12 ---
based on the prospective feasibility study (see table above). Using Fisher’s
exact test of equal proportions (test significance level of 0.05, power of 80%
and 1-sided), a minimum of 40 subjects was required with 20 subjects in each
group.
For the pivotal study, 42 allogeneic stem cell transplant patients were enrolled
with at least 6 months of follow-up from three clinical sites. The first patient
was enrolled in May 2004 and follow-up through April 2005. A total of 54
subjects were enrolled. Twelve subjects were excluded from the excluded.
The table below listed the subjects enrolled, included and excluded from the
analysis.
# of Subjects Site 1 Site 2 Site 3 Total
Enrolled 10 20 24 54
Included 9 13 20 42
(21%) (31%) (48%)
Excluded 1 7 4 12
Reasons for exclusion
Ineligible* 0 1 0 1
HLA-A24 allele only** 1 0 2 3
Early non-CMV related death with 1-2 tetramer results 0 2 0 2
<150 days viral testing insufficient to determine if 0 2 2 4
recurrent viremia occurred
Lost to follow-up 0 2 0 2
*CMV negative recipient
** HLA-A24 tetramer not in study
All CMV tetramer tests were performed at the laboratories in the clinical sites
following standard protocol. Samples were collected bi-weekly from 28 days
post-transplant. The laboratories were trained and qualified using known
CMV tetramer samples. The study endpoint was recurrent or persistent CMV
infection or CMV Disease (CMVD) and was determined by standard methods
used by the study clinical sites for monitoring. The methods used were
quantitative CMV DNA PCR, pp65 antigenemia and shell vial culture assay.
CMV DNA PCR was used as a secondary assay for pp65 antigenemia and
shell vial culture for leukpoenic patients or when the sample could not be
tested within 24 hours or to verify the shell vial culture result. The following
criteria were used to define the patient’s CMV status: 1) CMV infection if the
CMV copy number was greater than an established threshold used for
implementation of anti-viral therapy (ranged from > 500 to > 10,000
copies/mL of plasma depending on the clinical site), or ≥ 2 positive cells per
200,000 PMNs or positive culture, 2) recurrent CMV infection was defined as
two or more episodes separated by negative CMV test results, 3) persistent
CMV infection was defined as positive results for four or more weeks and 4)
CMVD was defined as biopsy proven organ involvement or CMV in
bronchoalveolar lavage fluid. The study analyzed recurrent or persistent
CMV infection or CMVD occurring after the rise of CMV-specific CD8+ T
cells to determine whether these cells were protective against CMV infection.

[Table 1 on page 12]
# of Subjects	Site 1	Site 2	Site 3	Total
Enrolled	10	20	24	54
Included	9
(21%)	13
(31%)	20
(48%)	42
Excluded	1	7	4	12
Reasons for exclusion				
Ineligible*	0	1	0	1
HLA-A24 allele only**	1	0	2	3
Early non-CMV related death with 1-2 tetramer results	0	2	0	2
<150 days viral testing insufficient to determine if
recurrent viremia occurred	0	2	2	4
Lost to follow-up	0	2	0	2

--- Page 13 ---
The maximum response of any individual allele/tetramer in an individual
patient was used in the analysis. All subjects meeting the inclusion criteria
with 3 or more blood samples or early death with CMV complications were
included in the analysis. Statistical analyses were performed using SAS
System software. Relative risk of recurrent or persistent CMV infection or
CMVD was calculated. Predictive power of possible risk factors was also
assessed by univariate and multivariate logistic models.
The 42 stem cell transplant recipients consisted of 18 males (43%) and 24
females (57%). The median age of the subjects were 48y (mean ± SD = 49y ±
11y) ranged from 19y to 65y. Thirty-eight were Caucasians, 2 Indians, 1
Asian and 1 not specified. Sixty-four percent (27/42) of the subjects were
HLA A*0201, 40% (17/42) A*0101, 36% (15/42) B*0801, 19% (8/42)
B*0702 and 7% (3/42) B*3501. The tetramer percents and absolute counts
for the serial blood samples over time for all alleles for all subjects are
summarized in table below.
CD3+CD8+ CMV Tetramer+ CD3+CD8+ CMV Tetramer+
(%) (cells/μL)
Number of Tetramer Results 638 635*
Median 1.43 3.2
Mean ± SD 4.02 ± 6.12 20.0 ± 43.2
Range 0.00-36.53 0.00-274.9
Upper 95th percentile 15.01 108.7
* CD8+ absolute counts unavailable for 3 subjects
The correlation between absolute counts and percentages of CMV
tetramer+CD8+ T cell was also analyzed by regression analysis and shown to
be y = 5.58x – 2.51 with a correlation coefficient of 0.79. Due to the highly
variable total CD8+ T cell counts in SCT patients, the absolute count appeared
to be a more accurate measure of CMV immune status and should be used for
assessing risk and management of patient post SCT.
Tetramer results of all patients were evaluated 50 to 100 days post-transplant.
Day 65 was determined to be the best time point to assess recovery of CMV
response since there were sufficient number of blood draws per patient for the
analysis (100% of patients had ≥ 2 samples and 83% had ≥ 3) and time points
after Day 65 could not distinguish patients with “rapid recovery” from those
with “delayed recovery”. The tetramer threshold of 7 cells/µL for predicting
risk was determined by evaluation of a range of CMV tetramer+ T cell counts
in “rapid recovery” patients (see table below).
Tetramer+ % Rapid Recovery Patients with Fisher’s Relative Risk
Threshold Recurrent or Persistent CMV Exact (Confidence Limits)
(cells/µL) Infection or CMVD p value
2 25.8 0.09 2.1 (0.9-4.7)
3 24.1 0.06 2.2 (1.0-5.1)
4 16.7 0.01* 3.3 (1.2-8.9)

[Table 1 on page 13]
	CD3+CD8+ CMV Tetramer+
(%)	CD3+CD8+ CMV Tetramer+
(cells/μL)
Number of Tetramer Results	638	635*
Median	1.43	3.2
Mean ± SD	4.02 ± 6.12	20.0 ± 43.2
Range	0.00-36.53	0.00-274.9
Upper 95th percentile	15.01	108.7

[Table 2 on page 13]
Tetramer+
Threshold
(cells/µL)	% Rapid Recovery Patients with
Recurrent or Persistent CMV
Infection or CMVD	Fisher’s
Exact
p value	Relative Risk
(Confidence Limits)
2	25.8	0.09	2.1 (0.9-4.7)
3	24.1	0.06	2.2 (1.0-5.1)
4	16.7	0.01*	3.3 (1.2-8.9)

--- Page 14 ---
Tetramer+ % Rapid Recovery Patients with Fisher’s Relative Risk
Threshold Recurrent or Persistent CMV Exact (Confidence Limits)
(cells/µL) Infection or CMVD p value
5 16.7 0.01* 3.3 (1.2-8.9)
6 16.7 0.01* 3.3 (1.2-8.9)
7 14.3 0.01* 3.7 (1.2-11.3)
8 17.7 0.07 2.5 (0.8-7.6)
*Statistically significant
Study results summarized in table below show that 21 of the 42 SCT patients
had ≥ 7 cells/µL between Day 28 and Day 65 post transplant. Only 3 patients
(14%) in this group had recurrent or persistent CMV infection or CMVD. The
remaining 21 patients had < 7 cells/µL and 52% (11/21) developed recurrent
or persistent CMV infection or CMVD (see table below).
Recurrent or Persistent CMV Infection or CMVD
No Yes Total
Delayed Recovery 10 11 21
< 7 cells/µL
Rapid Recovery 18 3 21
≥ 7 cells/µL
Total 28 14 42
Data also showed that of the 14 patients with recurrent or persistent CMV
infection or CMVD, 64% (9/14) had events occurred within the first 100 days
post transplant.
The risk of recurrent or persistent CMV infection or CMVD for CMV
tetramer+ CD8+ T cells of < 7 cells/µL is 52.4% and for CMV tetramer+
CD8+ T cells of ≥ 7 cells/µL is 14.3%. Therefore, the relative risk is 3.7
(95% CI 1.2-11.3) for patients with < 7 cells/µL CMV tetramer+ CD8+ T
cells.
Reproducibility:
Intra-assay imprecision – Each site tested a unique CMV specimen with
known reactivity to HLA A*0201 CMV tetramer. The sample was analyzed
in triplicate by three operators (Site 1 and 2) and 2 operators (Site 3). Each
site used a different flow cytometer – FC500 (Site 1), FACSCalibur (Site 2)
and EPICS XL (Site 3). Intra-assay imprecision results for CMV tetramers
were within the acceptable limits of ≤ 20% and are shown below. In addition,
percents CV of absolute counts of CD3+CD8+ cells were < 10% ranging from
2.4% to 6.9%.
CMV Tetramer+ CMV Tetramer+
(%) (celle/μL)
Site Operator System N Mean %CV Mean %CV
1 1 FC500 3 3.02 7.3 7.0 4.5
2 4.60 10.8 13.9 10.8

[Table 1 on page 14]
Tetramer+
Threshold
(cells/µL)	% Rapid Recovery Patients with
Recurrent or Persistent CMV
Infection or CMVD	Fisher’s
Exact
p value	Relative Risk
(Confidence Limits)
5	16.7	0.01*	3.3 (1.2-8.9)
6	16.7	0.01*	3.3 (1.2-8.9)
7	14.3	0.01*	3.7 (1.2-11.3)
8	17.7	0.07	2.5 (0.8-7.6)

[Table 2 on page 14]
	Recurrent or Persistent CMV Infection or CMVD		
	No	Yes	Total
Delayed Recovery
< 7 cells/µL	10	11	21
Rapid Recovery
≥ 7 cells/µL	18	3	21
Total	28	14	42

[Table 3 on page 14]
Site	Operator	System	N	CMV Tetramer+
(%)		CMV Tetramer+
(celle/μL)	
				Mean	%CV	Mean	%CV
1	1	FC500	3	3.02	7.3	7.0	4.5
	2			4.60	10.8	13.9	10.8

--- Page 15 ---
CMV Tetramer+ CMV Tetramer+
(%) (celle/μL)
Site Operator System N Mean %CV Mean %CV
3 4.66 5.3 18.12 6.9
1 3.90 17.4 14.7 15.7
2 2 FACSCalibur 3 2.79 11.4 8.7 11.4
3 2.99 8.3 9.9 8.3
1 4.02 2.11 16.9 4.9
3 EPICS XL 3
2 4.47 5.37 18.3 3.1
Inter-laboratory reproducibility – EDTA blood specimens from three donors
of know tetramer percents. HLA specificity for the low tetramer activity was
HLA A*0201, for mid tetramer activity was HLA A*0101 and for high
tetramer activity was HLA B*0702. Samples were stabilized for 7 days and
shipped overnight to 5 clinical sites for testing. The clinical sites consisted of
the three sites from the intra-assay precision study, BCI and a Canadian
laboratory. The specimens were tested within 1-7 days. For each clinical site,
assay was tested with one replicate and by one operator. Results were within
the acceptable limits of ≤ 20% for CMV tetramer+ results and ≤ 15% for
CD3+CD8+ absolute counts.
Clinical performance across sites – CD3+CD8+ CMV tetramer absolute
counts from patients with recurrent or persistent CMV infection or CMVD
were compared separately from those without. Results showed that patients
with recurrent or persistent CMV infection or CMVD had lower tetramer+
cell counts. None of the nine patients in Site 1 developed recurrent or
persistent CMV infection or CMVD because the pre-transplant conditioning
regimen used was reduced intensity and non-myeloablative which resulted in
higher post-transplant white blood cell counts and possibly accounted for
faster recovery of CMV immunity. Site 2 and 3 on the other hand used
myeloablative regimens.
4. Clinical cut-off:
CMV tetramer+ CD8+ T cells ≥ 7 cells/µL at Day 65 post-transplant.
5. Expected values/Reference range:
The expected reference range was established using the A*0101, A*0201,
B*0702, B*0801 and B*3501 CMV tetramers on whole blood samples from 36
CMV sero-negative and 36 CMV sero-positive donors. A total of 99 distinct
results were obtained, consisting of 57 sero-negative and 42 sero-positive results
using the appropriate allele matched tetramers for each donor. Samples were
tested in duplicate. Results showed that the reference range for CMV sero-
negative subjects was 0 to 0.75 CMV tetramer+ cells/µL or 0% to 0.158% CMV
tetramer+ percent and for CMV sero-positive subjects the reference range was 0
to 46.57 tetramer+ cells/µL or 0.005% to 8.635% CMV tetramer+ percent (see
results below).

[Table 1 on page 15]
Site	Operator	System	N	CMV Tetramer+
(%)		CMV Tetramer+
(celle/μL)	
				Mean	%CV	Mean	%CV
	3			4.66	5.3	18.12	6.9
2	1	FACSCalibur	3	3.90	17.4	14.7	15.7
	2			2.79	11.4	8.7	11.4
	3			2.99	8.3	9.9	8.3
3	1	EPICS XL	3	4.02	2.11	16.9	4.9
	2			4.47	5.37	18.3	3.1

--- Page 16 ---
CMV sero-negative (57) CMV sero-positive (42) Total (99)
Tetramer+ % Tetramer+ % tetramer+ Tetramer+ %
absolute tetramer+ absolute absolute tetramer+
counts counts counts
(cells/µL) (cells/µL) (cells/µL)
Mean 0.09 0.026 6.96 1.507 3.00 0.652
SD 0.16 0.03 9.49 1.79 7.02 1.37
Median 0.03 0.01 4.03 0.845 0.12 0.040
Range 0-0.75 0-0.158 0.01-46.57 0.005-8.635 0-46.57 0-8.635
Upper 0.19 0.074 24.50 5.40 11.39 2.84
95th
Percentile
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.

[Table 1 on page 16]
	CMV sero-negative (57)		CMV sero-positive (42)		Total (99)	
	Tetramer+
absolute
counts
(cells/µL)	%
tetramer+	Tetramer+
absolute
counts
(cells/µL)	% tetramer+	Tetramer+
absolute
counts
(cells/µL)	%
tetramer+
Mean	0.09	0.026	6.96	1.507	3.00	0.652
SD	0.16	0.03	9.49	1.79	7.02	1.37
Median	0.03	0.01	4.03	0.845	0.12	0.040
Range	0-0.75	0-0.158	0.01-46.57	0.005-8.635	0-46.57	0-8.635
Upper
95th
Percentile	0.19	0.074	24.50	5.40	11.39	2.84